铁死亡在非酒精性脂肪性肝病发病中作用的研究进展

doi:10.16352/j.issn.1001-6325.2024.02.0260

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (2): 260-264.doi: 10.16352/j.issn.1001-6325.2024.02.0260

铁死亡在非酒精性脂肪性肝病发病中作用的研究进展

肖艳新¹, 刘岩², 许岭翎³, 周亚茹^2*

1.保定市第一中心医院内分泌科,河北保定 071000;
2.河北医科大学附属第三医院内分泌科,河北石家庄 050051;
3.中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室,北京 100730

收稿日期:2023-09-21 修回日期:2023-11-24 发布日期:2024-02-05
通讯作者: ^*Sunday47@163.com
基金资助:
河北省自然科学基金(H2021206073)

Research progress on the role of ferroptosis in the pathogenesis of non-alcoholic fatty liver disease

XIAO Yanxin¹, LIU Yan², XU Lingling³, ZHOU Yaru^2*

1. Department of Endocrinology,Baoding NO.1 Central Hospital, Baoding 071000;
2. Department of Endocrinology, the Third Hospital of Hebei Medical University, Shijiazhuang 050051;
3. Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2023-09-21 Revised:2023-11-24 Published:2024-02-05
Contact: ^*Sunday47@163.com

摘要/Abstract

摘要： 铁死亡是近年提出的一种新型细胞死亡方式,其主要特征为铁过载及脂质过氧化。铁死亡参与非酒精性脂肪性肝病的发生发展。铁过载可通过芬顿反应产生大量活性氧,在脂氧合酶的作用下,肝细胞膜上的不饱和脂肪酸发生脂质过氧化,从而诱导肝细胞死亡,导致非酒精性脂肪性肝病/非酒精性脂肪性肝炎的发生。阻断铁死亡可能成为保护肝细胞的治疗策略之一。

关键词: 铁死亡, 非酒精性脂肪性肝病, 脂质过氧化, 铁过载

Abstract: Ferroptosis is a new type of cell death proposed in recent years, and its main characteristics are iron overload and lipid peroxidation. Ferroptosis is involved in the occurrence and development of non-alcoholic fatty liver disease(NAFLD). Iron overload can generate a large amount of reactive oxygen species through the Fenton reaction. Under the action of lipoxygenase, the unsaturated fatty acids on the liver cell membrane undergo lipid peroxidation, which induces liver cell death and leads to the occurrence of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Blocking ferroptosis may provide one of the therapeutic strategies to protect liver cells.

Key words: ferroptosis, non-alcoholic fatty liver disease, lipid peroxidation, iron overload

中图分类号:

R589.2

肖艳新, 刘岩, 许岭翎, 周亚茹. 铁死亡在非酒精性脂肪性肝病发病中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 260-264.

XIAO Yanxin, LIU Yan, XU Lingling, ZHOU Yaru. Research progress on the role of ferroptosis in the pathogenesis of non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2024, 44(2): 260-264.

参考文献

[1]Zhang L, Dai X, Wang L, et al. Iron overload accelerated lipid metabolism disorder and liver injury in rats with non-alcoholic fatty liver disease[J]. Front Nutr, 2022, 9:961892. doi:10.3389/fnut.2022. 961892.
[2]Wei S, Qiu T, Wang N, et al. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis[J]. Environ Res,2020,188:109824. doi: 10.1016/j.envres. 2020.109824.
[3]Hu Q, Wei W, Wu D, et al. Blockade of GCH1/BH4 axis activates ferritinophagy to mitigate the resistance of colorectal cancer to erastin-induced ferroptosis[J]. Front Cell Dev Biol,2022, 10:810327. doi:10.3389/fcell.2022.810327.
[4]Yu Y, Jiang L, Wang H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis[J]. Blood, 2020, 136: 726-739. doi:10.1182/blood.2019002907. doi:10.1182/blood.2019002907.
[5]Hoki T, Miyanishi K, Tanaka S, et al. Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis[J]. Hepatology,2015,62:751-761. doi:10. 1002/hep.27774
[6]Sabrina N, Bai CH, Chang CC, et al. Serum iron: ferritin ratio predicts healthy body composition and reduced risk of severe fatty liver in young adult women[J]. Nutrients,2017,9:833. doi:10.3390/nu9080833.
[7]Wang L, Sun M, Cao Y, et al. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overload[J]. Arch Biochem Biophys, 2020, 695:108642. doi:10.1016/j.abb. 2020.108642.
[8]Lanthier N, Molendi-Coste O, Horsmans Y, et al. Kupf-fer cell activation is a causal factor for hepatic insulin resistance[J]. Am J Physiol Gastrointest Liver Physiol, 2010,298:107-116. doi:10.1152/ajp gi.00391.2009.
[9]Cheng K, Huang Y, Wang C. 1,25(OH)2D3 inhibited ferroptosis in zebrafish liver cells (ZFL) by regulating Keap1-Nrf2-GPx4 and NF-κB-hepcidin axis[J]. Int J Mol Sci,2021,22:11334. doi:10.3390/ijms 222111334.
[10]Zheng R, Lin C, Mao Y, et al. miR-761-hepcidin/Gpx4 pathway contribute to unexplained liver dysfunction in polycystic ovary syndrome by regulating liver iron overload and ferroptosis[J]. Gynecol Endocrinol, 2023,39:2166483. doi:10.1080/09513590.2023.2166483.
[11]Duan J, Wang Z, Duan R, et al. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice[J]. Hepatology,2022,75:140-153. doi:10.1002/ hep.32148.
[12]Zhang XJ, She ZG, Wang J, et al. Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis[J]. Sci Transl Med,2021,13:eabg8117. doi:10.1126/scitranslmed.abg8117.
[13]Wenzel SE, Tyurina YY, Zhao J, et al. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals[J]. Cell, 2017, 171:628-641.e26. doi:10.1016/j.cell.2017.09.044.
[14]Sun WY, Tyurin VA, Mikulska-Ruminska K, et al. Phospholipase iPLA2β averts ferroptosis by eliminating a redox lipid death signal[J]. Nat Chem Biol,2021,17:465-476. doi:10.1038/s41589-020-00734-x.
[15]兰斌,龚盛强,成绍武,等.铁死亡的机制及其在相关疾病中的意义[J].基础医学与临床,2018,38:1337-1341.doi:1001-6325(2018)09-1337-05.
[16]Zhu Z, Zhang Y, Huang X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4[J]. Eur J Pharmacol,2021,908:174351. doi:10.1016/j.ejphar.2021. 174351.
[17]Gao G, Xie Z, Li EW, et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis[J]. J Nat Med, 2021,75:540-552. doi:10. 1007/s11418-021-01491-4.
[18]Yang Y, Chen J, Gao Q, et al. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease[J]. Toxicology, 2020, 445:152599. doi:10.1016/j.tox.2020. 152599.
[19]Chen GH, Song CC, Pantopoulos K, et al. Mitochondrial oxidative stress mediated Fe-induced ferroptosis via the NRF2-ARE pathway[J]. Free Radic Biol Med, 2022,180:95-107. doi:10.1016/j.freeradbiomed.2022.01. 012.
[20]Qi J, Kim JW, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice[J]. Am J Pathol, 2020,190:68-81. doi:10.1016 /j.ajpath.2019.09.011.
[21]Tong J, Li D, Meng H, et al. Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease[J]. Acta Pharm Sin B, 2022, 12:3 650-3666. doi:10.1016/j.apsb.2022.02.003.
[22]Li S, Zhuge A, Wang K, et al. Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice[J]. Front Pharmacol, 2022, 13:1081553. doi:10.3389/fphar.2022. 1081553.
[23]Anthonymuthu TS, Tyurina YY, Sun WY, et al. Resolv-ing the paradox of ferroptotic cell death: Ferrostatin-1 binds to 15LOX/PEBP1 complex, suppresses generation of peroxidized ETE-PE, and protects against ferroptosis[J]. Redox Biol, 2021,38:101744. doi:10.1016/j.redox.2020. 101744.
[24]Kim JH, Lewin TM, Coleman RA. Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones[J]. J Biol Chem, 2001,276:24667-24673. doi:10.1074/jbc.M010793200.
[25]Carlson BA, Tobe R, Yefremova E, et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration[J]. Redox Biol,2016,9:22-31. doi:10.1016/j.redox.2016.05.003.
[26]Anegawa D, Sugiura Y, Matsuoka Y, et al. Hepatic resistance to cold ferroptosis in a mammalian hibernator Syrian hamster depends on effective storage of diet-derived α-tocopherol[J]. Commun Biol, 2021,4:796. doi:10.1038/s42003-021-02297-6.

铁死亡在非酒精性脂肪性肝病发病中作用的研究进展

Research progress on the role of ferroptosis in the pathogenesis of non-alcoholic fatty liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙立杰, 郝丹丹. 诱导肝星状细胞铁死亡治疗肝纤维化的研究进展[J]. 基础医学与临床, 2024, 44(1): 108-113.
[2]	李想, 李晔. 非酒精性脂肪性肝病中自噬与铁死亡相互作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1294-1298.
[3]	王鑫瑞, 秦燕. Ghrelin在代谢性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1299-1303.
[4]	郝丹丹, 张垒, 白春英. 靶向铁死亡治疗非酒精性脂肪性肝病的研究进展[J]. 基础医学与临床, 2023, 43(8): 1317-1321.
[5]	楚晓云, 蔡成. 铁死亡在新生儿急性肺损伤中作用机制的研究进展[J]. 基础医学与临床, 2023, 43(6): 1008-1011.
[6]	闫霖, 陆珏秀, 罗颖, 刘先霞. BM-MSCs来源外泌体介导铁死亡减轻大鼠心肌细胞系H9c2缺氧/复氧损伤[J]. 基础医学与临床, 2023, 43(5): 771-776.
[7]	向彩霞, 黄彬涛, 郝建. 抗凋亡抑制剂维奈克拉在治疗髓系白血病的研究进展[J]. 基础医学与临床, 2023, 43(5): 833-836.
[8]	曲大鹏, 孙会艳, 李强, 王洪权. 铁死亡在蛛网膜下腔出血早期脑损伤发病机制中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 486-489.
[9]	黄李晨露, 张家瑞, 郑永钦, 贺军栋. 钠-葡萄糖共转运蛋白2抑制剂在非酒精性脂肪性肝病中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1594-1598.
[10]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.
[11]	薛晋芳, 宋海飞, 陈国兵. 程序性细胞死亡在脓毒症发生发展中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1284-1287.
[12]	徐娟, 李晔. 铁死亡在阿尔茨海默病中作用的研究进展[J]. 基础医学与临床, 2022, 42(7): 1129-1133.
[13]	胡诗琪, 蓝彦琦, 吴寿岭, 王晓墨, 陈朔华, 汪国栋, 王丽. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42(5): 788-794.
[14]	王冯宇, 李亘, 林晓伊, 姚欣悦, 陈毓. 铁死亡在肿瘤治疗作用中的研究进展[J]. 基础医学与临床, 2022, 42(11): 1781-1784.
[15]	许可, 胡珦, 虞伟慧, 杨丽娟, 顾雪疆. 代谢健康型肥胖与非酒精性脂肪性肝病患病率的相关性[J]. 基础医学与临床, 2021, 41(6): 837-841.